ALRN - Aileron Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.04
+0.02 (+0.33%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.02
Open5.66
Bid0.00 x 800
Ask0.00 x 1300
Day's Range5.65 - 6.18
52 Week Range4.90 - 15.48
Volume565,754
Avg. Volume45,282
Market Cap89.014M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.33
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.25
Trade prices are not sourced from all markets
  • GlobeNewswire27 days ago

    Aileron Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

    Aileron Therapeutics (ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that Manuel Aivado, CMO and CSO, will present at the Jefferies 2018 Global Healthcare Conference being held in New York, NY. ALRN-6924 is a first-in-class product candidate designed to reactivate wild type p53 tumor suppression by disrupting the interactions between p53 and the two primary p53 suppressor proteins, MDMX and MDM2. Aileron believes ALRN-6924 is the first and only product candidate in clinical development that can equipotently bind to and disrupt the interaction of MDMX and MDM2 with p53.

  • GlobeNewswirelast month

    Aileron Therapeutics Announces Publication of ALRN-6924 Nonclinical Data in T-cell Lymphomas by Researchers at Dana-Farber Cancer Institute

    Aileron Therapeutics (ALRN), the leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced the publication of nonclinical results in Nature Communications demonstrating the anti-cancer potential of ALRN-6924 in models of T-cell lymphoma (TCL). ALRN-6924 is designed to reactivate p53-mediated tumor suppression by targeting the two primary p53 suppressor proteins, MDM2 and MDMX. ALRN-6924 is being evaluated in Phase 1 and Phase 2 clinical trials in patients with peripheral T-cell lymphoma (PTCL) and acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

  • GlobeNewswirelast month

    Aileron Therapeutics Announces Changes to Management

    Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that Joseph A. Yanchik III has resigned as President and Chief Executive Officer of the Company and as a member of its Board of Directors. Biopharma industry veteran John P. Longenecker, Ph.D. has been named interim Chief Executive Officer. “I would like to thank Joe on behalf of the Board of Directors for his 12 years of service to Aileron,” said Jeff Bailey, Chairman of Aileron’s Board of Directors.

  • GlobeNewswire2 months ago

    Aileron Therapeutics Reports First Quarter 2018 Financial Results

    Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today reported business highlights and financial results for the first quarter ended March 31, 2018. “The clinical activity and safety seen in our interim data from our ongoing Phase 2a clinical trial of ALRN-6924, in addition to our Phase 1 data, continue to support the clinical importance of p53 and the potential of ALRN-6924 in solid and liquid tumors where there is significant need for new treatment options.

  • GlobeNewswire2 months ago

    Aileron Therapeutics Announces Publication by Researchers at Albert Einstein College of Medicine of ALRN-6924 Nonclinical Data in Acute Myeloid Leukemia

    CAMBRIDGE, Mass., April 11, 2018-- Aileron Therapeutics, the clinical stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced the publication of nonclinical ...

  • GlobeNewswire3 months ago

    Aileron Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

    CAMBRIDGE, Mass., April 02, 2018-- Aileron Therapeutics, the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today reported business highlights and financial ...

  • GlobeNewswire3 months ago

    Aileron Therapeutics Announces Expansion of Scientific Advisory Board

    CAMBRIDGE, Mass., March 28, 2018-- Aileron Therapeutics, the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases, today announced that three leading oncology ...

  • American City Business Journals9 months ago

    Boston biotech developing obesity drug pulls down $120M in IPO

    A 9-year-old biotech company headquartered in Boston’s Back Bay, Rhythm Pharmaceuticals Inc. has become the fourth local drugmaker to go public this year, raising $120 million in an upsized public offering. Rhythm, which has 15 employees based in a 6,830-square-foot office at 500 Boylston St., sold 7 million shares for $17 each, beating the range it floated in a federal filing just a couple weeks ago of $14-$16. It’s the second-biggest IPO for a Boston-area biotech in what’s so far a slow year, with only Cambridge-based Akcea Therapeutics (AKCA) raising more, with a $144 million IPO in July .

  • GuruFocus.comlast year

    The Largest Insider Trades of the Week

    Tyler Technologies, Oracle among stocks traded by insiders

  • TheStreet.comlast year

    Here's the Latest on Four New Biotech IPOs

    Four biotech companies recently joined the Nasdaq.